The Relevance of Polar Surface Area (PSA) in Rationalizing Biological Properties of Several cis‐Diamminemalonatoplatinum(II) Derivatives

A panel of six cis‐diamminemalonatoplatinum(II) derivatives were designed and synthesized, and their physicochemical properties and in vitro biological activity were experimentally evaluated and studied in silico. All the complexes showed higher IC50 values (≥20 μM) than those observed for cisplatin and its malonato analogue on three different human tumor cell lines, namely A2780 ovarian carcinoma, A549 lung carcinoma, and MCF‐7 breast carcinoma. In silico studies revealed that polar surface area (PSA) is the best descriptor to explain the poor biological activity observed for this series of new compounds, which in turn is likely due to poor cellular uptake. This finding is in line with general rules that assign a major role to PSA in characterizing the transport properties of drugs, in the actual case of antiproliferative metallopharmaceuticals.

[1]  Domenico Osella,et al.  The influence of temperature on antiproliferative effects, cellular uptake and DNA platination of the clinically employed Pt(II)-drugs. , 2008, Journal of inorganic biochemistry.

[2]  D. Osella,et al.  Stepwise assembly of platinum–folic acid conjugates , 2008 .

[3]  Zijian Guo,et al.  Towards the rational design of platinum(II) and gold(III) complexes as antitumour agents. , 2008, Dalton transactions.

[4]  R. Mannhold,et al.  Lipophilicity Descriptors for Structure‐Property Correlation Studies: Overview of Experimental and Theoretical Methods and a Benchmark of log P Calculations , 2008 .

[5]  Raimund Mannhold,et al.  Molecular Drug Properties: Measurement and Prediction , 2007 .

[6]  Peter Ertl,et al.  Polar Surface Area , 2007 .

[7]  D. Osella,et al.  Bioinorganic Chemistry: The Study of the Fate of Platinum-Based Antitumour Drugs , 2007 .

[8]  Stephen J Lippard,et al.  Direct cellular responses to platinum-induced DNA damage. , 2007, Chemical reviews.

[9]  J. Schellens,et al.  Phase I and pharmacokinetic trial of AP5346, a DACH–platinum–polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients , 2007, Cancer Chemotherapy and Pharmacology.

[10]  Bernhard Lippert,et al.  Cisplatin : chemistry and biochemistry of a leading anticancer drug , 2006 .

[11]  D. Nowotnik,et al.  Synthesis and characterization of AP5346, a novel polymer-linked diaminocyclohexyl platinum chemotherapeutic agent. , 2006, Bioconjugate chemistry.

[12]  Domenico Osella,et al.  The RP-HPLC measurement and QSPR analysis of logP(o/w) values of several Pt(II) complexes. , 2006, Journal of inorganic biochemistry.

[13]  D. Osella,et al.  Synthesis and characterisation of estrogenic carriers for cytotoxic Pt(II) fragments: biological activity of the resulting complexes. , 2005, Organic & biomolecular chemistry.

[14]  M. Jakupec,et al.  Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches. , 2005, Current medicinal chemistry.

[15]  Elena Monti,et al.  Cytotoxicity of cis-platinum(II) conjugate models. The effect of chelating arms and leaving groups on cytotoxicity: a quantitative structure-activity relationship approach. , 2005, Journal of medicinal chemistry.

[16]  J. Schellens,et al.  A Phase I and Pharmacological Study of the Platinum Polymer AP5280 Given as an Intravenous Infusion Once Every 3 Weeks in Patients with Solid Tumors , 2004, Clinical Cancer Research.

[17]  A. Gabizon,et al.  Folate-targeted PEG as a potential carrier for carboplatin analogs. Synthesis and in vitro studies. , 2003, Bioconjugate chemistry.

[18]  D. Siluk,et al.  Chromatographic retention parameters in medicinal chemistry and molecular pharmacology. , 2003, Current medicinal chemistry.

[19]  Grietje Molema,et al.  Drug Targeting: Organ-Specific Strategies , 2001 .

[20]  J. Borrell,et al.  Synthesis and biological activity of 7-oxo substituted analogues of 5-deaza-5,6,7,8-tetrahydrofolic acid (5-DATHF) and 5,10-dideaza-5,6,7,8-tetrahydrofolic acid (DDATHF). , 2001, Journal of medicinal chemistry.

[21]  J. Platts,et al.  Calculation of the hydrophobicity of platinum drugs. , 2001, Journal of medicinal chemistry.

[22]  F. Rochon,et al.  Synthesis and characterization of Pt(II) complexes with amine and carboxylato ligands. Crystal structure of (1,1-cyclobutanedicarboxylato)di(ethylamine)platinum(II)·H2O , 2000 .

[23]  C. Giandomenico,et al.  Current status of platinum-based antitumor drugs. , 1999, Chemical reviews.

[24]  A. Cailleux,et al.  Mechanisms of reaction of L‐methionine with carboplatin and oxaliplatin in different media: a comparison with cisplatin , 1999, Biopharmaceutics & drug disposition.

[25]  D. Tzemach,et al.  Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies. , 1999, Bioconjugate chemistry.

[26]  Y. Sohn,et al.  Linkage Isomerism Dependent on Solvent and Temperature. Synthesis and Structural Properties of Diamineplatinum(II) Complexes of Allyl- and Diallylmalonate Ligands. , 1999, Inorganic chemistry.

[27]  J. Borrell,et al.  Synthesis and biological activity of 4-amino-7-oxo-substituted analogues of 5-deaza-5,6,7,8-tetrahydrofolic acid and 5,10-dideaza-5, 6,7,8-tetrahydrofolic acid. , 1998, Journal of medicinal chemistry.

[28]  P. Low,et al.  Synthesis, purification, and tumor cell uptake of 67Ga-deferoxamine--folate, a potential radiopharmaceutical for tumor imaging. , 1996, Bioconjugate chemistry.

[29]  W. J. Lambert.  Modeling oil-water partitioning and membrane permeation using reversed-phase chromatography , 1993 .

[30]  M. Desai,et al.  Polymer bound EDC (P-EDC): A convenient reagent for formation of an amide bond , 1993 .

[31]  J. Blum,et al.  Multinuclear (platinum-195, nitrogen-15, carbon-13) NMR studies of the reactions between cis-diaminediaquaplatinum(II) complexes and aminomalonate , 1990 .

[32]  Z. Kaminski.  2-Chloro-4,6-dimethoxy-1,3,5-triazine. A New Coupling Reagent for Peptide Synthesis , 1988 .

[33]  D A Scudiero,et al.  Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. , 1988, Cancer research.

[34]  K. Ninomiya,et al.  Diphenylphosphoryl azide. A new convenient reagent for a modified Curtus reaction and for the peptide synthesis. , 1972, Journal of the American Chemical Society.

[35]  R. J. Doerksen,et al.  Topological polar surface area: a useful descriptor in 2D-QSAR. , 2009, Current medicinal chemistry.

[36]  R. Gust,et al.  Preclinical and clinical studies on the use of platinum complexes for breast cancer treatment. , 2007, Anti-cancer agents in medicinal chemistry.

[37]  D. Kerwood,et al.  Activation of carboplatin by carbonate. , 2006, Chemical research in toxicology.

[38]  D. Osella,et al.  Uptake of antitumor platinum(II)-complexes by cancer cells, assayed by inductively coupled plasma mass spectrometry (ICP-MS). , 2004, Journal of inorganic biochemistry.

[39]  H. Reile,et al.  Chemosensitivity of human MCF-7 breast cancer cells to diastereoisomeric diaqua(1,2-diphenylethylenediamine) platinum(II) sulfates and specific platinum accumulation , 2004, Cancer Chemotherapy and Pharmacology.

[40]  H. McLeod,et al.  Handbook of Anticancer Pharmacokinetics and Pharmacodynamics , 2004, Cancer Drug Discovery and Development.

[41]  Vladimir P. Torchilin,et al.  Biomedical aspects of drug targeting , 2002 .

[42]  Z. Kaminski.  Triazine-based condensing reagents. , 2000, Biopolymers.

[43]  L S Hollis,et al.  Chemical and biological properties of a new series of cis-diammineplatinum(II) antitumor agents containing three nitrogen donors: cis-[Pt(NH3)2(N-donor)Cl]+. , 1989, Journal of medicinal chemistry.

[44]  T Braumann,et al.  Determination of hydrophobic parameters by reversed-phase liquid chromatography: theory, experimental techniques, and application in studies on quantitative structure-activity relationships. , 1986, Journal of chromatography.

[45]  J. Hoeschele,et al.  Studies on the antitumor activity of group VIII transition metal complexes. Part I. Platinum (II) complexes , 1973 .